Orphazyme burned through millions of dollars in futile fight for success

Biotech is an expensive business, something Orphazyme can attest to. Over the years, it spent hundreds of millions of dollars developing its main asset, without ever crossing the finish line.

Photo: Nikolaj Skydsgaard/Reuters/Ritzau Scanpix

Despite its best efforts, biotech firm Orphazyme never managed to make an approved drug out of its candidate arimoclomol. This was despite the firm spending billions of kroner on the candidate.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs